Accessibility Menu
Oncolytics Biotech logo

Oncolytics Biotech

(NASDAQ) ONCY

Current Price$0.94
Market Cap$92.05M
Since IPO (2001)-98%
5 Year-68%
1 Year+33%
1 Month+13%

Oncolytics Biotech Financials at a Glance

Market Cap

$92.05M

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$35.52M

EPS (TTM)

-$0.25

P/E Ratio

-3.64

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$0.94

Volume

946,940.341

Open

$0.91

Previous Close

$0.92

Daily Range

$0.91 - $0.98

52-Week Range

$0.62 - $1.51

Estimated Earnings Date

Aug 6, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oncolytics Biotech

Industry

Biotechnology

Employees

29

CEO

Jared Kelly

Headquarters

Calgary, AB T2R 0C5, CA

ONCY Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

5214.36%

Return on Capital

N/A

Return on Assets

-435.28%

Earnings Yield

-27.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$92.05M

Shares Outstanding

100.36M

Volume

946.94K

Avg. Volume

1.30M

Financials (TTM)

Gross Profit

-CA$119.31K

Operating Income

-CA$35.48M

EBITDA

-CA$36.08M

Operating Cash Flow

-CA$30.89M

Capital Expenditure

-CA$15.65K

Free Cash Flow

-CA$30.89M

Cash & ST Invst.

CA$5.49M

Total Debt

CA$508.00K

Oncolytics Biotech Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$22.31K

-17.4%

Gross Margin

0.00%

N/A

Market Cap

$92.05M

N/A

Market Cap/Employee

$3.17M

N/A

Employees

29

N/A

Net Income

-CA$12.89M

-92.8%

EBITDA

-CA$12.92M

-87.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$5.49M

-64.1%

Total Debt

CA$508.00K

-49.2%

Accounts Receivable

CA$961.00K

+979.8%

Inventory

CA$0.00

N/A

Long Term Debt

CA$342.00K

-51.8%

Short Term Debt

CA$166.00K

-42.8%

Return on Assets

-4.35%

N/A

Return on Invested Capital

-12.96%

N/A

Free Cash Flow

-CA$10.17M

-56.5%

Operating Cash Flow

-CA$10.17M

-56.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COYACoya Therapeutics, Inc.
$5.39+1.89%
CLNNClene Inc.
$5.77-2.04%
TILInstil Bio, Inc.
$7.56+0.00%
TVGNTevogen Bio Holdings Inc.
$10.01+1.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$16.15+0.00%
NOKNokia
$13.72-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.76-0.09%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.29+0.09%

Questions About ONCY

What is the current price of Oncolytics Biotech?

Oncolytics Biotech is trading at $0.94 per share.

What is the 52-week range for Oncolytics Biotech?

Over the past 52 weeks, Oncolytics Biotech has traded between $0.62 and $1.51.

How much debt does Oncolytics Biotech have?

As of the most recent reporting period, Oncolytics Biotech reported total debt of CA$508.00K.

How much cash does Oncolytics Biotech have on hand?

Oncolytics Biotech reported CA$5.49M in cash and cash equivalents in its most recent financial results.

What is Oncolytics Biotech’s dividend yield?

Oncolytics Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.